753246
Last Update Posted: 2012-12-03
Recruiting has ended
All Genders accepted | 18 Years-70 Years |
150 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Nimotuzumab in Adults With Glioblastoma Multiforma
Determination of efficiency of nimotuzumab in adults with glioblastoma multiforma
The objective of the present study is a comparison of treatment of patients with newly diagnosed glioblastoma multiforme grade IV. Patients will be randomized in one of two arms when included. Patients randomly assigned to arm A will receive Nimotuzumab (OSAG 101) plus Temozolomide concomitant with standard radiotherapy. Patients randomised in arm B will receive standard radiotherapy plus Temozolomide treatment.
Eligibility
Relevant conditions:
Adults With Glioblastoma Multiforma
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov